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Abstract
The synthesis of a GSK 2nd generation inhibitor of the hepatitis C virus, by enantioselective 1,3-dipolar cycloaddition between a
leucine derived iminoester and tert-butyl acrylate, was studied. The comparison between silver(I) and gold(I) catalysts in this reac-
tion was established by working with chiral phosphoramidites or with chiral BINAP. The best reaction conditions were used for the
total synthesis of the hepatitis C virus inhibitor by a four step procedure affording this product in 99% ee and in 63% overall yield.
The origin of the enantioselectivity of the chiral gold(I) catalyst was justified according to DFT calculations, the stabilizing
coulombic interaction between the nitrogen atom of the thiazole moiety and one of the gold atoms being crucial.
Introduction
The prevalence of chronic hepatitis C virus (HCV) infection is
such that it is estimated to be suffered by around 200 million
people worldwide [1]. This enveloped single-stranded RNA
virus (belonging to the Flaviviridae family) is present in six
major genotypes in the world’s industrialized nations,
genotype 1 being the most prevalent, followed by genotype 2
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Scheme 1: Retrosynthetic analysis of antiviral structures.
and 3. Due to the poor toleration of the current therapy, and the
lack of an appropriate vaccine, researchers working on strate-
gies for developing antivirals have tried to attack viruses at
every stage of their life cycles, namely attachment to a host cell,
replication of viral components, assembly of viral components
into complete viral particles and release of viral particles able to
infect new hosts cells. Inside the infected hepatocytes, struc-
tural E1 and E2 and non-structural proteins such as NS2, NS3
(which bear serine proteinase, helicase, and NTPase activities),
NS4A, NS4B, NS5A (regulators of RNA replication), and
NS5B (the RNA-dependent RNA polymerase) are generated
[2,3] and, in fact, constitute the main targets. At the moment,
there are many drugs under clinical trial evaluation, the com-
pounds targeting HCV replication being the most promising
candidates to achieve a sustained virological response [1,4].
Several years ago, a high-throughput screening of the Glaxo-
SmithKline compound collection identified a series of small
pyrrolidine molecules, e.g., 1 (Figure 1), able to inhibit the
RNA-dependent RNA polymerase of the virus responsible for
hepatitis C (genotype 1g) [5]. Thus, their high replication rates
(billions of copies per day) can be drastically suppressed by the
inhibition of the NS5B RNA-dependent RNA polymerase
enzyme, which is the primary target for oral antiviral agents
[6,7]. In further studies, a second generation of antiviral agents
2 and 3 (Figure 1), offering a greater dynamic range even for
HCV genotype 1b, was published [5,8,9]. These molecules
incorporated a 2-thiazole heterocycle instead of the 2-thienyl
group, together with a more hydrophobic environment at the
amido group [9-12]. However, the design of improved broader
spectrum compounds, capable of effective inhibition of geno-
types 1a and 1b, is desirable. In this sense, GSK625433 (4)
(Figure 1) has exhibited a good pharmacokinetic profile in
preclinical animal species [13].
The synthesis of the endo-pyrrolidine core of 5 is the key step
for the preparation of these antiviral agents, and can be effi-
ciently achieved by a 1,3-dipolar cycloaddition (1,3-DC) be-
tween the corresponding azomethine ylide and an alkyl acrylate
[14-18] (Scheme 1). The first synthesis of racemic product 1,
Figure 1: More active GSK HCV inhibitors.
and other derivatives including compounds 2, was achieved in
several steps using, as the key reaction, the silver(I) or
lithium(I)-metalloazomethine ylide, under basic conditions, and
tert-butyl acrylate. The enantiomeric samples were isolated by
semi-preparative chiral HPLC [9,10]. The first endo-diastereos-
elective synthesis of the key precursor 5a (HetAr = 2-thienyl),
of the antiviral agent 1 (96% de), was achieved by our group
from imine 6a (HetAr = 2-thienyl; R1 = Me) in the presence of
the acrylate derived from (R)-methyl lactate [19]. However, the
most straightforward, and also faster, approach to the enan-
tiomeric formation of this non-nucleosidic antiviral agent 1 is
based on a catalytic enantioselective 1,3-DC [20-24]. The first
reported enantioselective overall synthesis of the structure 1
was catalyzed by a chiral phosphoramidite and AgClO4 [25,26],
although the synthesis of the five-membered core has also been
published using chiral calcium complexes [27,28].
In addition, for the second generation antivirals 2 or 3, the effi-
ciency of the Lewis acid-catalyzed 1,3-DC, following the route
shown in Scheme 1, was combined with hydroquinine as chiral
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base (6 mol %) together with silver acetate (3 mol %), and this
afforded moderate enantioselectivities (70–74%) of 5b, in such
a way that a further 1,1’-binaphthyl-2,2’-dihydrogen phosphate
assisted chiral resolution was required to increase the optical
purity of the target molecule [11]. Chiral calcium(II) complexes
have been used for the synthesis of a similar key molecule 5b
(R1 = t-Bu, 88% ee), but the overall synthesis of the antiviral
drug was not reported [27,28].
In this article, we describe the full study concerning the enantio-
selective synthesis of product 5b using silver(I) or gold(I)
complexes, generated from chiral phosphoramidites or BINAP
as ligands, in order to prepare antiviral agent 2a.
Results and Discussion
The efficiency of the chiral phosphoramidite/silver(I) salts
[25,26,29] and BINAP/Ag(I) salts [30,31] in 1,3-DC, following
the general pattern shown in Scheme 1, has been demonstrated
by our group, establishing a wider scope and sensibly higher
enantioselectivities for the reactions performed in the presence
of chiral phosphoramidite/silver(I) complexes [24]. Concerning
enantioselective gold(I)-catalyzed 1,3-DC, the classical cyclo-
addition starting from iminoesters 6 has not been so extensively
explored. Reports of chiral transformations involving azlac-
tones [32,33] and iminoesters 6 [34], which employed chiral
diphosphines and gold(I) salts, have been published showing
very good endo-diastereoselectivities and moderate to excellent
enantioselectivities. However, the use of acrylates as dipo-
larophiles has only been explored with the 2-thienyliminoesters
6a.
Therefore, based on our experience of silver(I)- and gold(I)-
catalyzed 1,3-DC involving azomethine ylides derived from
α-iminoester 6b and tert-butyl acrylate, we selected a series of
known chiral phosphoramidite ligands (Figure 2), which were
prepared according to the literature [35]. The chiral phospho-
ramidite/silver(I) complexes were generated in situ by mixing
equimolar amounts of both components at room temperature for
30 min. Chiral phosphoramidite/AuCl complexes were gener-
ated according to the literature [36] and, finally, underwent
anion interchange in the presence of the corresponding silver
salt. The precipitate was filtered through a celite pad and used
without any other additional treatment.
All of the reactions were performed at room temperature,
employing a 5 mol % of both catalyst and base, for 17 h
(Scheme 1). Reactions between iminoester 6b and tert-butyl
acrylate, which employed silver complexes derived from
Monophos (Sa)-7 ligand, afforded racemic endo-cycloadduct 5b
(Table 1, entries 1–3). The analogous reaction catalyzed by
chiral phosphoramidite 7/gold(I) complexes did not occur at all
Figure 2: Chiral phosphoramidites tested in this study.
when AgClO4 or AgSbF6 were employed as anion interchange
agents. Just a small conversion, with some side products, and
null enantioselectivity was observed in the crude reaction
mixtures obtained when using (Sa)-7/AuTFA (Table 1, entry 4).
When the reaction was carried out in the presence of chiral
ligand (Ra,R)-8 the enantioselectivities were low or moderate in
the examples concerning AgClO4 and AgTFA (TFA = trifluo-
roacetate anion), respectively (Table 1, entries 5 and 7). Surpris-
ingly, the reaction involving this chiral ligand 8 combined with
AgSbF6 afforded a good yield of the enantiomerically pure
cycloadduct 5b (Table 1, entry 6). Attempts to increase the
enantioselectivity, in the example run with AgTFA, by
replacing triethylamine by diisopropylethylamine (DIPEA)
were not successful, and only a slight increment of enan-
tiomeric excess was observed (Table 1, entry 8). Again, the
gold complex (Ra,R)-8/AuTFA did not give the expected reac-
tion product (Table 1, entry 9). The employment of this
matched combination with (Ra,R)-8 was justified by the low
Beilstein J. Org. Chem. 2011, 7, 988–996.
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Scheme 2: Optimization of the reaction conditions for the synthesis of the key intermediate 5b.
enantioselectivity achieved through the use of (Ra,S)-8 in the
same transformation (not shown in Table 1). The widely used
chiral ligand (Sa,R,R)-9 has also been similarly studied. In this
case, the matched combination was determined in previous
works that investigated the scope of enantioselective silver(I)-
catalyzed 1,3-DC of azomethine ylides and dipolarophiles
[25,29]. The enantioselectivities were moderate, even when
using AgSbF6, and the effect of the added base was negligible
(Table 1, entries 10–14). The process catalyzed by the (Sa,R,R)-
9/AuTFA was not suitable (Table 1, entry 15). The more steri-
cally hindered chiral phosphoramidite (Sa,R,R)-10 did not afford
any interesting results because the conversions were extremely
low after 2 days reaction, and the crude reaction mixture was
very complex (1H NMR analysis) (Table 1, entries 16–18).
However, a good result was obtained when phosphoramidite
(Sa,R,R)-11 was tested together with AgClO4. The high enantio-
selectivity achieved for 5b (86% ee) is in contrast to the
racemic samples identified when either AgSbF6 or AgTFA were
employed as co-catalysts (Table 1, entries 19–21). Biphenol
derived ligand (R,R)-12 generally furnished good yields of the
cycloadduct 5b but with a low enantiodiscrimination (Table 1,
entries 22–24). In many examples, although the reactions were
performed at lower temperatures (0 or −20 °C, not shown in Ta-
ble 1) the resulting enantioselectivities did not suffer noticeable
variations. In all of the cases given in Table 1, the endo-
cycloadduct was exclusively generated, and the absolute con-
figuration of 5b was established by extrapolation with the
results previously obtained for each chiral catalyst [25,26,28-
30,33]. According to these results the combination of chiral
phosphoramidite and silver(I) salt is much more appropriate
than the analogous one made with gold(I) salts. Especially
useful is the reaction of (Ra,R)-8/AgSbF6 catalytic complex
affording enantiomerically pure cycloadduct endo-5b. It is
worth mentioning that chiral phosphoramidite/gold(I)
complexes, formed by anion interchange of the corresponding
phosphoramidite/AuCl complex and AgSbF6 [36] or AgBF4
[37,38], have been successfully employed in enantioselective
cycloaddition of allenedienes [36,37] or allenenes [38] under
very mild reaction conditions (0 ºC to r.t.). Despite these
described opportunities provided by chiral phosphoramidite
ligands as a part of gold(I) complexes, their activity (see
Table 1) was negligible, until now, when applied in the 1,3-DC
represented in Scheme 2.
Table 1: Optimization of the 1,3-dipolar cycloaddition of 6b and tert-
butyl acrylate using chiral phosphoramidite ligands.
Entry Catalysta Base Yieldb (%) eec (%)
1 (Sa)-7/AgClO4 Et3N ___d rac
2 (Sa)-7/AgSbF6 Et3N ___d rac
3 (Sa)-7/AgTFA Et3N ___d rac
4 (Sa)-7/AuTFA DIPEA ___d ___d
5 (Sa,R)-8/AgClO4 Et3N 82 20
6 (Sa,R)-8/AgSbF6 Et3N 82 99
7 (Sa,R)-8/AgTFA Et3N 82 60
8 (Sa,R)-8/AgTFA DIPEA 82 64
9 (Sa,R)-8/AuTFA DIPEA ___d ___d
10 (Sa,R,R)-9/AgClO4 DIPEA 86 30
11 (Sa,R,R)-9/AgSbF6 Et3N 72 40
12 (Sa,R,R)-9/AgSbF6 DIPEA 82 40
13 (Sa,R,R)-9/AgTFA Et3N 82 50
14 (Sa,R,R)-9/AgTFA DIPEA 82 40
15 (Sa,R,R)-9/AuTFA DIPEA ___d ___d
16 (Sa,R,R)-10/AgClO4 Et3N ___d rac
17 (Sa,R,R)-10/AgTFA Et3N ___d rac
18 (Sa,R,R)-10/AgSbF6 Et3N ___d rac
19 (Sa,R,R)-11/AgClO4 Et3N 72 86
20 (Sa,R,R)-11/AgSbF6 Et3N ___d rac
21 (Sa,R,R)-11/AgTFA Et3N ___d rac
22 (R,R)-12/AgClO4 Et3N 79 30
23 (R,R)-12/AgTFA Et3N 87 40
24 (R,R)-12/AgSbF6 Et3N 86 30
aThe generation of silver catalysts was achieved by mixing equimolar
amounts of silver(I) or gold(I) salt and the corresponding phospho-
ramidite. bAfter flash chromatography (silica gel). The observed
endo:exo ratio was always >98:2 (1H NMR). cDetermined by using
analytical chiral HPLC columns (Daicel, Chiralpak AS). dNot deter-
mined.
The chiral ligand (Sa)-BINAP (13) was also tested in the stan-
dard reaction to access key molecule endo-5b (Scheme 3).
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Scheme 3: Preparation of the enantiomerically enriched 5b.
AgClO4 was found to be the most appropriate silver salt to
achieve the highest enantioselectivity (88% ee) compared to the
results obtained when other silver salts were employed (Table 2,
entries 1, 3, and 4). In agreement with the previous results, the
reaction with chiral silver complexes at lower temperatures did
not improve the enantioselectivity. According to our previous
work, dimeric chiral gold(I) catalyst [(Sa)-BINAPAuTFA]2
(Sa,Sa)-14 was very efficient in 1,3-DC compared to other cata-
lysts with different stoichiometry or anion nature. The gold
complex (Sa,Sa)-14 was prepared according to the literature [39]
and immediately used in the cycloaddition in the absence of
base because of its bifunctional behaviour, namely the acti-
vation of the basic character of the dipole [34]. However, no
reaction occurred under these conditions (Table 2, entry 5).
Therefore, the presence of the base was crucial for the evolu-
tion of the reaction, as can be seen in entries 6 and 7 of Table 2.
Triethylamine promoted the reaction affording good yield and
good enantioselectivity (78% ee). However, DIPEA-mediated
cycloaddition did not improve the enantioselectivity of the
resulting endo-cycloadduct 5b. Unlike the results obtained with
silver(I) catalytic complexes at lower temperatures (0 or
−20 °C), the gold(I)-catalyzed cycloaddition could be success-
fully carried out at 0 °C resulting in excellent enantiodiscrimin-
ation (99% ee) to the detriment of the reaction time, which had
to be increased to 3 days (Table 2, entry 8). The result obtained
in this last example was excellent but the enantiomeric excess
achieved at room temperature in the reaction performed with
(Sa)-13/AgClO4 complex is also valuable.
With the most enantiomerically enriched cycloadduct 5b, the
synthesis of the antiviral agent 2a could be accomplished in two
conventional steps involving an amidation reaction and a double
Table 2: Optimization of the 1,3-dipolar cycloaddition of 6a and tert-
butyl acrylate using chiral (Sa)-BINAP (13) ligand.
Entry Catalysta Base Yieldb (%) eec (%)
1 (Sa)-13/AgClO4 Et3N 78 88
2 (Sa)-13/AgClO4 Et3Nd 75 85
3 (Sa)-13/AgSbF6 Et3N 79 72
4 (Sa)-13/AgTFA Et3N 82 40
5 (Sa,Sa)-14 ___ ___e ___e
6 (Sa,Sa)-14 Et3N 90 78
7 (Sa,Sa)-14 DIPEA 87 70
8 (Sa,Sa)-14 Et3Nd,f 92 99
aThe generation of silver catalysts was achieved by mixing equimolar
amounts of silver(I) and (Sa)-BINAP. bAfter flash chromatography
(silica gel). The observed endo:exo ratio was always >98:2 (1H NMR).
cDetermined using analytical chiral HPLC columns (Daicel, Chiralpak
AS). dReaction performed at 0 °C. eNot determined. fAfter 3 days reac-
tion.
ester hydrolysis. The latter step consisted of a first stage TFA-
mediated hydrolysis of the tert-butyl ester followed by a basic
stage employing a refluxing solution of KOH/MeOH
(Scheme 4). The final product 2b was finally isolated in 68%
overall yield (from pyrrolidine 5b) and with 99% ee, or alter-
natively in 63% overall yield from iminoester 6b.
Although the study of the enantioselectivity exhibited by chiral
phosphoramidite/silver(I) complexes employing DFT calcula-
tions was confirmed by our group [25], an explanation for the
excellent results obtained employing the gold complex (Sa,Sa)-
14 (Table 2, entry 8) was needed. In a previous work, we
demonstrated that the stereoselectivity of the 1,3-DC employing
chiral metallic Lewis bases arises from the blockage of one of
Beilstein J. Org. Chem. 2011, 7, 988–996.
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Scheme 4: Total synthesis of antiviral agent 2b.
Figure 3: Gibbs activation energy and main geometrical features of the computed ylide and transition structures (TS) corresponding to the 1,3-DC of
the Au(I)–ylide complex and tert-butyl acrylate computed at ONIOM(B3LYP/LanL2DZ:UFF) level of theory. High-level and low-level layers are repre-
sented as ball & stick and wireframe models, respectively. Grey numbers in parentheses represent Mulliken charges. Distances are in Å.
the prochiral faces [40]. In this way, our results (in terms of
DFT calculations) show that there is only one energetically
accessible conformation due to the high substitution of the
leucine-derived ylide (Figure 3). In this reactive complex there
is an effective blockage of the (2re,5si) prochiral face of the
ylide. Therefore, the predicted stereochemical outcome corre-
sponds to the exclusive formation of the (2S,4S,5R)-5b
cycloadduct, the same as that obtained experimentally.
As shown in Figure 3, the reaction proceeds to a concerted but
highly asynchronous cycloaddition in which the endo-approach
of the dipolarophile is favoured due to a stabilizing interaction
of the carboxylic group and the metallic centre. The computed
activation Gibbs free energy barrier associated with the forma-
tion of (2S,4S,5R)-5b is 23.4 kcal mol−1, which means that the
process is feasible at the reaction temperature. It is worth noting
that there is a stabilizing coulombic interaction between the
nitrogen atom of the thiazole moiety (N7) and one of the gold
atoms of the catalyst, both in the TS and the ylide complex.
This interaction fixes the planar conformation of the ylide
moiety and minimizes the possible steric hindrance with the
bulky tert-butyl group of the dipolarophile. When a phenyl
substituent is placed to the imino group this planar con-
formation does not exist and, in consequence, a more steric
interaction avoids the approach of the mentioned dipolarophile.
Conclusion
In this work the complexity of the 1,3-DC reaction of azome-
thine ylides and dipolarophiles (in this case acrylates) was
demonstrated. There are many parameters to control and a small
variation can cause a dramatic effect in the overall enantiodis-
crimination of the process. The temperature does not equally
affect silver(I) and gold(I) catalysts. The effect of the hetero-
cycle remains crucial in these transformations because, origi-
nally, the enantioselectivity of the reaction between methyl
benzylideneiminoglycinate and alkyl acrylates failed in the
presence of the silver(I) or the dimeric gold(I) complexes
derived from chiral BINAP. The metal cation and the counter-
ion are also important in the final result and, in certain cases,
their position with respect to the reaction centre can modify the
Beilstein J. Org. Chem. 2011, 7, 988–996.
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overall reaction and consequently alter the enantioselectivity of
the process. To date, the best reaction conditions to access GSK
2nd generation antiviral drugs 2a are: The employment of chiral
phosphoramidite (Ra,R)-8/AgSbF6 and Et3N (both in 5 mol %
amount) at r.t. for 2 h, or chiral (Sa,Sa)-14 gold complex and
Et3N (both in 5 mol % amount) at 0 °C for 3 days. Whilst phos-
phoramidite complexes operated exclusively in the presence of
silver salts, the most versatile chiral BINAP ligand could work
efficiently with both silver(I) or gold(I) cations. The stabilizing
coulombic interaction between the nitrogen atom of the thia-
zole moiety and one of the gold atoms of the catalyst both in the
TS and the ylide complex is the explanation for the success of
the gold-catalyzed cycloaddition, in constrast to the observed
TS involving methyl benzylideneiminoleucinate.
Experimental
General. All reactions were carried out in the absence of light.
Anhydrous solvents were freshly distilled under an argon
atmosphere. Aldehydes were also distilled prior to use for the
elaboration of the iminoesters. Melting points were determined
with a Reichert Thermovar hot plate apparatus and are uncor-
rected. Only the structurally most important peaks of the IR
spectra (recorded on a Nicolet 510 P-FT and on a Jasco FTIR
4100) are listed. 1H NMR (300 MHz) and 13C NMR (75 MHz)
spectra were obtained on a Bruker AC-300 using CDCl3 as
solvent and TMS as internal standard, unless otherwise stated.
Optical rotations were measured on a Perkin Elmer 341
polarimeter. HPLC analyses were performed on a JASCO 2000-
series equipped with a chiral column (detailed for each com-
pound in the main text), using mixtures of n-hexane/isopropyl
alcohol as mobile phase, at 25 °C. Low-resolution electron
impact (EI) mass spectra were obtained at 70 eV on a Shimadzu
QP-5000 and high-resolution mass spectra were obtained on a
Finnigan VG Platform. HRMS (EI) were recorded on a
Finnigan MAT 95S. Microanalyses were performed on a Perkin
Elmer 2400 and a Carlo Erba EA1108. Analytical TLC was
performed on Schleicher & Schuell F1400/LS silica gel plates
and the spots were visualized under UV light (λ = 254 nm). For
flash chromatography we employed Merck silica gel 60
(0.040–0.063 mm). Ligands 7–12 were prepared according to
the reported procedure (see text). All of the transformations
performed with silver catalysts were performed in the absence
of light. The synthesis of the already characterized chiral com-
plex (Sa,Sa)-14 was performed according to the published
procedure [39].
Computational methods. Hybrid QM/MM calculations for
optimizations of saddle points were performed in terms of
ONIOM [41-43] method implemented in GAUSSIAN09 suite
of programs [44]. Ball & stick model in Figure 3 shows atoms
included in the high-level layer, and a wire model is used to
represent atoms included in the low-level layer. In the high-
level layer, the electron correlation was partially taken into
account by using the hybrid functional B3LYP [45-50]
combined with Hay-Wadt small core effective potential (ECP)
[51] basis set. UFF [52] molecular mechanics force field was
employed in the low-level layer. Thermal corrections of Gibbs
free energies were computed at the same level of theory and
were not scaled. All stationary points were characterized by
harmonic analysis. Reactant intermediates and cycloadducts
have positive definite Hessian matrices. Transition structures
show only one negative eigenvalue in their diagonalized force
constant matrices, and their associated eigenvectors were
confirmed to correspond to the motion along the reaction co-
ordinate under consideration.
1,3-Dipolar cycloaddition of iminoester 6b and tert-butyl
acrylate. General procedure. To a solution of the in situ
prepared chiral gold complex or chiral silver complex
(0.05 mmol) in toluene (2 mL) was added, at r.t., a solution of
the iminoester 6b (120 mg, 0.5 mmol) and tert-butyl acrylate
(109 μL, 0.75 mmol) in toluene (2 mL). In some cases DIPEA
or triethylamine (0.05 mmol) was added (see Tables) and the
mixture stirred at r.t. or 0 °C for 2 or 3 days (see Tables). The
reaction mixture was filtered off through a celite pad, the
organic filtrate was directly evaporated and the residue was
purified by recrystallization or by flash chromatography,
yielding pure endo-cycloadduct 5b.
(2S,4S,5R)-4-tert-Butyl-2-methyl-2-isobutyl-5-(thiazol-2-
yl)pyrrolidine-2,4-dicarboxylate (5b): Colourless solid; mp
>195 °C dec (n-hexane/ethyl acetate); [α]D20 +43 (c 1.00,
CH2Cl2, 99% ee by HPLC); IR (neat) νmax: 3330, 1718 cm−1;
1H NMR (300 MHz, CDCl3) δ 7.70, 7.27 (2 × d, J = 3.4 Hz,
2H, CHCHS), 4.83 (d, J = 7.5 Hz, 1H, CHCS), 3.73 (s, 3H,
OCH3), 3.41 (q, J = 7.8 Hz, 1H, CHCHN), 3.25 (br. s, 1H, NH),
2.79, 2.10 (2 × dd, J = 13.5, 7.9 Hz, 2H, CH2CCO), 1.76–1.69
(m, 2H, CH2CH), 1.54–1.48 (m, 1H, CH2CH), 1.17 (s, 9H,
(CH3)3), 0.94, 0.85 (2 × d, J = 6.2 Hz, 6H, 2 × CH3C); 13C
NMR (75 MHz, CDCl3) δ 176.2, 170.8, 170.6 (2 × CO and
CSN), 142.4, 118.8 (CHCHS), 80.6 (C(CH3)3), 68.3 (COCN),
61.7 (CHCS), 52.2 (OCH3), 49.6 (CHCO), 49.3 (CH2CCO),
39.5 (CH2CH), 27.6 ((CH3)3), 25.0 (C(CH3)2), 24.3, 22.9 (2 ×
CH3C); EIMS m/z (% relative intensity): 368 (M+, 1), 310 (51),
295 (16), 255 (23), 254 (14), 253 (100); HRMS calcd for
C18H28N2O4S, 368.1770; found, 368.1761; HPLC (Chiralpak
AD-H), n-hexane:iPrOH 95/5, 1 mL/min, λ = 225 nm, tR,maj =
12 min, tR,min = 18 min.
Synthesis of the antiviral agent 2b. Compound (2S,4S,5R)-5b
(1.2 mmol, 441 mg) was dissolved in dichloromethane (25 mL),
and pyridine (2.4 mmol, 174 μL) and 4-(trifluoromethyl)-
Beilstein J. Org. Chem. 2011, 7, 988–996.
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benzoyl chloride (1.2 mmol, 182 μL) were slowly added at
0 °C. The resulting mixture was refluxed for 1 day and the
solvent was removed under vacuo (15 Torr). Crude compound
(2S,4S,5R)-15, was allowed to react with trifluoroacetic acid/
dichloromethane mixture (9.6 mL/18 mL). The resulting mix-
ture was stirred at r.t. overnight and the solvent evaporated
under vacuo. The residue was dissolved in a 1 M solution of
KOH in a 4/1 MeOH/H2O (50 mL) and refluxed for 16 h.
Methanol was evaporated and aqueous HCl (0.5 M, 20 mL) and
ethyl acetate were added (2 × 20 mL). The combined organic
phases were dried (MgSO4) and evaporated, yielding the crude
compound (2S,4S,5R)-2b, which was recrystallized from a mix-
ture containing n-hexane/ethyl acetate.
(2S,4S,5R)-2-Isobutyl-5-(thiazol-2-yl)-1-[4-(trifluoromethyl)-
benzoyl]pyrrolidine-2,4-dicarboxylic acid (2b): Pale brown
solid; mp >130 °C dec (n-hexane/ethyl acetate); [α]D20 +35
(c 0.3, toluene, 99% ee); IR (neat) νmax: 3100, 1731,
1693 cm−1; 1H NMR (300 MHz, CD3COCD3) δ 8.15 (d, J =
7.5 Hz, 2H, ArH), 7.80–7.64 (m, 3H, ArH and CHCHS), 7.29
(d, J = 3.4 Hz, 1H, CHCHS), 5.85 (d, J = 8.7 Hz, 1H, CHNS),
4.01–3.81 (m, 1H, CHCO), 2.84 (t, J = 13.3 Hz, 1H, CH2CCO),
2.34 (dd, J = 13.2, 6.5 Hz, 1H, CH2CCO), 1.28 (m, 4H, CH2CH
and 2 × OH), 1.14–1.06 (m, 1H, CH2CH), 0.85 (m, 6H, 2 ×
CH3C); 13C NMR (75 MHz, CDCl3) δ 172.4, 169.1, 168.9,
167.4 (3 × CO and CNS), 141.1, 134.2, 134.1, 130.2, 126.9,
125.4, 120.9, (ArC, CF3, and CHCHS), 69.7 (COCN), 65.3
(NCH), 51.39 (CHCO), 42.3 (CH2CCO), 35.3 (CH2CH), 25.7
(CH(CH3)2), 24.4, 24.2 (CH(CH3)2); ESIMS m/z (% relative
intensity) 470 (M+, 2); HRMS calcd for C21H21F3N2O5S,
470.4620; found, 470,4631; HPLC (Chiralpak AD-H),
n-hexane:iPrOH 85/15, 0.1 mL/min, λ = 250 nm), tR,maj =
12.5 min, tR,min = 15.5 min.
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